GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$51.60
0.94 (1.86%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
4d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GSK is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: GSK is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.47
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$40.65
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $51.60, which is considered extended relative to its 30-day fair value range of $48.62 to $50.55. The stock's valuation (Forward PE: 10.5) is in line with its historical norms (10.4). At these levels, the market is pricing in 0.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $51.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $51.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$48.62 -
$50.55
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding GSK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($51.98)
- NEUTRAL: Market pricing in 0.3% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$48.62 -
$50.55
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$47.62
Resistance Level
$51.69
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
10.51
Wall Street Target
$51.98
(+2.6%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
23.2%
Profit Margin
17.1%
Valuation Premium vs History
+0.3% premium
PE vs Historical
10.5 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.3%
(market-implied from PE analysis)
1-Year Target
$50.81
(+0%)
2-Year Target
$50.96
(+1%)
3-Year Target
$51.12
(+1%)
3-Yr Target (if PE normalizes)
(PE: 11→10)
PE COMPRESSION
$50.56
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 7.0%)
$131.69
(+160%)
Base:
(SPY PE: 10.5, Growth: 7.0%)
$62.09
(+23%)
Bear:
(PE: 8.9, Growth: 7.0%)
$52.78
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 13.96 | Current EPS (TTM): $3.64
Bull Case
$73.97
(+46%)
Analyst growth 32.4%, PE expands to 15.4
Base Case
$67.24
(+33%)
Market implied 32.4%, PE stable at 14.0
Bear Case
$34.54
(-32%)
Severe decline -20.0%, PE contracts to 11.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:53 PM ET
Data refreshes hourly during market hours. Next update: 6:53 PM
Data refreshes hourly during market hours. Next update: 6:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Val T. Hoyle
SELL
2025-09-23
Lisa C. McClain
BUY
2025-08-04
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced GSK Option Strategies
Professional options setups generated by AI based on today's GSK price and gamma walls.
